{
  "trial_id": "NCT00134680",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "postmenopausal",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "tumor cell expression of ER and/or PR and ErbB2",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "at least one bidimensionally measurable lesion",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "ECOG performance status 0-2",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "patient should have life expectancy of 6 months",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "patient must have adequate hematologic function: absolute neutrophil count (ANC) 1000/mm3; platelets 75,000/mm3",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "patient must have adequate renal and liver function",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "patient must give written informed consent prior to initiation of any invasive study-related procedures that would otherwise not be performed, and must be able to comply with scheduled visits and evaluations",
      "label": "met",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "prior treatment with trastuzumab",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "prior anthracycline exposure in adjuvant setting > 360 mg/m2",
      "label": "unknown",
      "evidence": ""
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "61",
    "trial_id": "NCT00134680",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}